Steven Rubis

In a report published Monday, Stifel analyst Steven Rubis initiated coverage of Computer Programs & Systems, Inc. (NASDAQ: CPSI) with a Hold rating and no assigned price target as the company's fourth quarter results suggested the business model faces uncertainty. "We are uncertain of CPSI's...

Stifel issued a report initiating coverage on Cerner Corporation (NASDAQ: CERN). Stifel rates Cerner as a Hold while a price target is unavailable. Analyst Steven Rubis wrote, "We believe consensus presupposes Cerner represents one of the best positioned HCIT companies set to benefit from increased...

In a report published Tuesday, Stifel analyst Steven Rubis reiterated a Buy rating on Medidata Solutions, Inc. (NASDAQ: MDSO), and raised the price target from $55.00 to $60.00. In the report, Stifel noted, "On Tuesday, March 17, Medidata Solutions met with several institutional investors. We were...

In a report published Thursday, Stifel analyst Steven Rubis reiterated a Buy rating on athenahealth (NASDAQ: ATHN), and raised the price target from $155.00 to $180.00. In the report, Stifel noted, “athenahealth announced the acquisition of RazorInsights, a cloud-based EHR and financial solutions...

In a report published Thursday, Stifel analyst Steven Rubis downgraded the rating on WebMD Health Corp. (NASDAQ: WBMD) from Buy to Hold, and removed the $52.00 price target. In the report, Stifel noted, “We are downgrading shares of WebMD from Buy to Hold, as the preponderance of evidence...

In a report released Thursday, Stifel analyst Steven Rubis downgraded eHealth (NASDAQ: EHTH) from Hold to Sell. Analysts at Stifel downgrade eHealth due to market uncertainty. eHealth investors predict a 78 percent year-over-year decline in submitted applications and revenue at seven percent...

In a report published Wednesday, Stifel analyst Steven Rubis upgraded the rating on WebMD Health (NASDAQ: WBMD) from Hold to Buy, and named a $60.00 price target. In the report, Stifel noted, “Our upgrade stems from strong industry macro trends and our view that current estimates for 3Q14 and 4Q14...